))
2: Twice the Targets, A Newly Approved Bispecific Enters the Myeloma Arena
Manage episode 492662847 series 3675738
Content provided by The HEII. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The HEII or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Regeneron has officially entered the multiple myeloma arena with FDA approval of Lynozyfic, a BCMA-targeted bispecific antibody for patients who’ve exhausted standard therapies. In this episode, we break down what Lynozyfic is, how it works, and how it stacks up against competitors.
6 episodes
Share
